CompletedPhase 4ACTRN12606000058572

Early Intervention in Acute Renal Failure

A multi-site randomised phase IV study to evaluate the effectiveness of intravenous erythropoietin in preventing intensive care unit patients with acute kidney injury from developing acute renal failure.

Sponsor

The Health Research Council of New Zealand

Enrollment

130 participants

Start Date

Jan 23, 2006

Study Type

Interventional

Conditions

Acute Renal Failure

Summary

Patients admitted to a general intensive care unit and high risk post cardiothoracic surgery patients will be screened for renal injury using urinary biomarkers and randomised within 6 hours of admission to two doses of placebo or erythropoietin at 24 hour intervals. Subjects, investigators and treating clinicians will be blinded to treatment throughout the study.

Eligibility

Sex: Both males and femalesMin Age: 16 Yearss

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying: Early Intervention in Acute Renal Failure. It may be open to adults aged 16 and older who meet certain criteria, including: Gamma Glutamyl Transpeptidase X Alkaline Phosphatase index of >46.3 u/mmol. Participation typically involves medical assessments, possible treatment with the study intervention, and follow-up visits to track your health.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.